NCT03069326 - A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Myelofibrosis

Interventions

DRUG

Ruxolitinib

Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.

DRUG

Thalidomide

Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

77030

Md Anderson Cancer Center, Houston

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale